Business Wire

Arthur D. Little: Nord Stream 2 Provides Economic Benefits, Generates Innovation and Helps to Develop Contractors’ Businesses

Jaa

The second part of a recent report from Arthur D. Little (ADL) – “Nord Stream 2 economic impact in the construction phase” – analyzes the economic effects (job creation and GDP) of the ongoing project to build two new gas pipelines from Russia to Germany. The report, which is a follow-up to an earlier report created in 2017, analyzes the current status of project investment and concludes that the total economic benefit to the European Union (EU) represents €9.9 billion for building the pipelines. In comparison to the first report (2017), which was carried out in the procurement phase, more than twice as much CAPEX has now been committed and spent in several EU and non-EU countries now that the project is in the middle of construction. More than 1,000 contractors from all over Europe and Russia are contributing to the realization of the project. This includes both large international firms providing materials or construction services and small enterprises providing expert services. Furthermore, the investment until the end of December 2018 creates 57,500 full-time job equivalents in the EU over five years, adding €4.7 billion in GDP in various industrial sectors.

Nord Stream 2 is a major natural gas infrastructure project that aims to build a pipeline system with 55 bcm per year of transport capacity. It will safely and reliably export gas to the European market, where demand is stable but indigenous production is decreasing, creating an import gap.

The objective of the new Arthur D. Little study, commissioned by Nord Stream 2, is to understand the direct, indirect and induced effects of the project on the European economy, and on countries where actual investments in the pipeline have been or are being made in more detail. Compared to the previous report, the current one takes actual spent and detailed supplier data until the beginning of operations into account.

It estimates the effects related to the execution of the project, as well as those on supply chains and the wider economy. The analysis used an economic modeling tool (IMPLAN) based on underlying statistical databases for different economies. The study considers all committed and spent investments as of the end of December 2018 of (CAPEX) €8 billion.

The most pronounced effects are seen in countries where major project-related construction activities are taking place – Russia, Germany, Finland, Denmark and Sweden; in countries traditionally associated with the offshore oil and gas industry that host the majority of service providers – the Netherlands, the United Kingdom, Norway and Italy; and at the headquarters of the project developer and other international service providers. The current study was complemented with supplier interviews which confirmed the beneficial impact the project has had on corporate development and local communities. Also highlighted in the study were some of the major innovations and pioneering solutions for challenges that resulted from project work.

Michael Kruse, Partner in ADL’s Energy & Utilities Practice, said: “At a time when the oil and gas industry is experiencing cut-backs and lay-offs, this report transparently demonstrates the benefits of large energy infrastructure projects such as Nord Stream 2.”

The report can be downloaded here: www.adl.com/NordStream2impact.

Contact information

Cate Bonthuys
Catalyst Comms
+447746546773
cate@catalystcomms.co.uk

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Algomi ALFA Delivering Actionable Liquidity with Liquidnet and Trumid18.6.2019 15:06:00 EESTTiedote

Algomi, which provides data aggregation technology for the optimization of fixed income liquidity, today announced Algomi ALFA will enable orders to be executed on Liquidnet and Trumid. With this new functionality, Algomi ALFA goes beyond aggregating market data and liquidity to allow traders to efficiently navigate the markets and execute trades without duplicating steps across platforms. For actionable liquidity alerts, Algomi ALFA enables order staging and desktop interoperability. Algomi ALFA allows traders to engage with Liquidnet’s growing corporate bond liquidity on any actionable alert, by populating orders directly from ALFA before sending to Liquidnet via FIX. Liquidnet subsequently launches an active negotiation window to traders from its desktop application. Once the trade is completed, traders can view and export the execution report from ALFA. For Trumid, traders can engage with all Trumid actionable alerts from within Algomi ALFA, through Algomi’s graphical user interfac

AnyVision Closes $74 Million Series A with New Participation from M12 and DFJ Growth18.6.2019 14:10:00 EESTTiedote

AnyVision, a leading computer vision company specializing in face, body, and object-recognition software, today announced the close of its $74 million Series A financing round. New investment comes from M12, Microsoft’s venture fund, DFJ Growth and OG Technology Partners. As part of the Series A, AnyVision previously announced investment from LightSpeed Venture Partners, Robert Bosch GmbH, Qualcomm Ventures, and Eldridge Industries. AnyVision, founded in 2015, is a leading computer vision company specializing in face, body, and object-recognition software. AnyVision develops core software solutions that make all cameras smart. These solutions are agnostic to all cameras, computing frameworks, and use-cases. “There are very few times in business when you have the opportunity to build an entirely new industry alongside leading ecosystem players,” said Eylon Etshtein, CEO and Co-Founder of AnyVision. “We are fortunate to have the backing of chipmakers like Qualcomm, camera manufacturers s

IDEMIA Launches Augmented Vision, its Next Generation Video Analytics Application at IFSEC International18.6.2019 14:07:00 EESTTiedote

IDEMIA, the global leader in Augmented Identity, launches its video analytics application enhancing security in public and private places. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190618005513/en/ Credits: IDEMIA Augmented Vision supports security officers in identifying persons of interest in real-time, and helps speed up post-event investigations. This latest cutting-edge technology from IDEMIA will enhance security in transport hubs (airports, stations…), stadiums and arenas, retail and commercial buildings, as well as gaming and entertainment sites that face growing security challenges. The application is based on IDEMIA’s long-standing expertise in deep learning and biometrics for video and image analysis including IDEMIA’s facial recognition technology: a longstanding best-in-class combination of efficiency, scalability and accuracy for facial recognition as evidenced by IDEMIA’s leading position in the most rece

F-star Appoints Darlene Deptula-Hicks as Chief Financial Officer and Opens Office in Cambridge, MA18.6.2019 14:00:00 EESTTiedote

F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, today announces the appointment of Darlene Deptula-Hicks, MBA as Chief Financial Officer (CFO), succeeding Tolga Hassan, who is appointed to serve as F-star’s Chief Operating Officer. Darlene Deptula-Hicks joins F-star from Northern Biologics, Inc., a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody therapeutics in oncology. Previously, Darlene held CFO positions across both private and publicly listed US companies, including Pieris Pharmaceuticals Inc., Microline Surgical Inc. and T2 Biosystems Inc. She brings to F-star a proven track record of finance strategy and leadership, capital raising, industry knowledge and the ability to build strong strategic partnerships. Darlene Deptula-Hicks, CFO of F-star, said: “It is a very exciting time to be joining F-star given its evolution to a f

Norsk Titanium Receives Airbus Contract for Qualification and Production18.6.2019 13:00:00 EESTTiedote

Officials with Norsk Titanium (Norsk) announce today a contract award from Airbus for the Qualification and Serial Production of the first parts to be manufactured utilizing wire-based Direct Energy Deposition (DED) additive manufacturing technology. “We have worked closely with Airbus over several years to demonstrate the technological maturity and the industrial readiness of our Rapid Plasma Deposition™ (RPD™) process,” said Norsk President and CEO Michael Canario. “This contract award is structured to enable long-term, serial production immediately following qualification. Our Plattsburgh, New York facility, with the assistance of Airbus technical leadership, has been preparing for this moment and is eager to demonstrate a 21st century advanced additive manufacturing capability.” This qualification of Airbus parts will demonstrate the suitability of the DED additive manufacturing process for aircraft structural parts. It will formalize the process by which individual parts are produ

Axonics® Announces U.S. Food & Drug Administration Approves Use of Full-Body MRI for Pivotal Study Patients18.6.2019 13:00:00 EESTTiedote

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the U.S. Food & Drug Administration (“FDA”) approved the use of full-body magnetic resonance imaging (“MRI”) using 1.5 Tesla MRI scanners for clinical study patients implanted with the Axonics System. The approval was a result of a supplement filed by Axonics with the FDA under the Investigational Device Exemption (“IDE”) regarding the Company’s ARTISAN-SNM 129-patient pivotal clinical study. The FDA concluded that Axonics provided sufficient data to support full-body MRIs. Raymond W. Cohen, CEO of Axonics, commented, “Allowing full-body MRI scans for our clinical study patients means that none will have to undergo an explant of their neurostimulator device should they require an MRI. We view this as a very positive step by the FD

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme